News
Deciphera announces publication of Qinlock phase 1 study results in patients with gastrointestinal stromal tumor in Journal of Clinical Oncology.
Deciphera Pharmaceuticals, Inc. announced that the Journal of Clinical Oncology has published results from its Phase 1 study of Qinlock, the Company’s switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor (GIST).
The article, entitled "Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor (GIST): a phase 1 study of ripretinib," is now available online and will be published in a future print issue of Journal of Clinical Oncology. The publication highlighted results from the Company’s ongoing Phase 1 study of ripretinib in patients with second-line through fourth-line plus GIST.
These published results are from 142 GIST patients receiving 150 mg of ripretinib once daily (QD) as the starting dose, which is the dose utilized in both of the Company’s registration-enabling trials, INVICTUS and the ongoing INTRIGUE study, as of an August 31, 2019 data cutoff date. Results were consistent with those previously presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Condition: GIST
Type: drug